dotinurad   Click here for help

GtoPdb Ligand ID: 11389

Synonyms: FYU-981 | FYU981 | Urece®
Approved drug PDB Ligand
dotinurad is an approved drug (Japan (2018))
Compound class: Synthetic organic
Comment: Dotinurad, is a novel selective, orally bioavailable urate reabsorption inhibitor (SURI). It inhibits transport via the urate anion exchanger 1 (SLC22A12).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 83.06
Molecular weight 356.96
XLogP 2.86
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(N1CS(=O)(=O)c2c1cccc2)c1cc(Cl)c(c(c1)Cl)O
Isomeric SMILES O=C(N1CS(=O)(=O)c2c1cccc2)c1cc(Cl)c(c(c1)Cl)O
InChI InChI=1S/C14H9Cl2NO4S/c15-9-5-8(6-10(16)13(9)18)14(19)17-7-22(20,21)12-4-2-1-3-11(12)17/h1-6,18H,7H2
InChI Key VOFLAIHEELWYGO-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
In Japan and other Asian markets, dotinurad is indicated for patients with hyperuricemia/gout. It is not approved by the US FDA (as of July 2026).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT07089875 A Study of Dotinurad Versus Allopurinol in Participants With Gout Phase 3 Interventional Crystalys Therapeutics
NCT07089888 A Study of Dotinurad Versus Allopurinol in Tophaceous Gout Phase 3 Interventional Crystalys Therapeutics
NCT07535034 A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants Phase 2 Interventional Crystalys Therapeutics